Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022

Basel, Switzerland, November 4, 2022 – Alentis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough treatments for fibrotic diseases and cancer, today announced that there will be two presentations about the treatment of biliary disease and cancer using Claudin-1 monoclonal antibodies at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022, taking place from November 4th to 8th in Washington DC, USA.


Presenter: Marion Muller, MS, Inserm, U1110 and University of Strasbourg, France

Session: Parallel 22: Experimental and Translational Hepatobiliary Tumors

Date: Monday, November 7th

Time: 9:00 – 10:30 AM EST

This presentation investigates the role of Claudin-1 as an oncogenic driver and therapeutic target in intra- and extrahepatic cholangiocarcinoma (CCA) with target expression analyses in patients and PoC using anti-Claudin-1 mAbs in cell-line- and patient-derived xenograft mouse models as well as in human CCA cell lines. The results in patient-derived models provide robust pre-clinical proof of concept and rationale for the clinical development of therapeutic CLDN1-specific antibodies in CCA.


Presenter: Dr. Fabio Del Zompo, MD, Inserm U1110 and University of Strasbourg, France

Session: Parallel 36: Cholangiocentric Studies Targeting Biliary Disorders

Date: Monday, November 7th

Time: 4:30 – 6:00 PM EST

This presentation unravels Claudin-1 as a mediator and driver of Primary Sclerosing Cholangitis (PSC) – a progressive fibrotic disease of the biliary system with high risk to develop cholangiocarcinoma and unsatisfactory therapeutic options. Claudin-1 protein expression in injured cholangiocytes and the ductular reaction shows robust association with disease progression in patients. PoC studies with robust safety and efficacy in human cell-based and state-of-the-art mouse models provide the perspective for the clinical development of Claudin-1 specific antibodies for PSC in patients.

For those registered, the presentations will also be available on the meeting’s digital platform, here:

About Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for fibrotic diseases and associated cancers.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

Alentis is using its portfolio of unique monoclonal antibodies that are highly selective for exposed and non-junctional Claudin-1, a previously unexploited target that plays a key role in the pathology of fibrosis across organs as well as solid tumors, to develop a pipeline of novel mechanisms targeting advanced fibrosis and cancer. Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression by targeting the epithelial injury. Furthermore, the unique mechanism of action of the antibodies provides the opportunity to treat solid tumors.  

Alentis’s lead therapeutic candidate, Claudin-1 specific mAb ALE.F02, is in Phase 1 clinical studies for the treatment of advanced kidney, liver and lung fibrosis which are expected to read out in Q1 2023. These represent very large and expanding markets with high unmet need. The company is also developing monoclonal antibody ALE-C04 for solid tumors that is currently in pre-clinical development. In addition, Alentis’ proprietary discovery platform allows the identification of new targets and supports the fast development of new compounds for other CLDN-driven diseases.

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.

For more information, visit  

For more information please contact:

Alentis Therapeutics
Nathalie Graf-Tschupp

Consilium Strategic Communications (International)
Mary-Jane Elliott / Matthew Cole / Ashley Tapp
Tel: +44 (0) 20 3709 5700